Cerus Corp Exceeds Q1 Expectations, Boosts 2026 Revenue Outlook, and Announces CEO Succession
CERS sits 96% above its 52-week low of $1.15.
Summary
Cerus Corporation announced robust first-quarter 2026 financial results, significantly reducing its net loss and raising full-year product revenue guidance, alongside a planned CEO transition.
Key Events · Earnings and Guidance · CERS
-
Strong Q1 Financial Performance
Reported Q1 2026 total revenue of $59.9 million, up 23% year-over-year, and significantly reduced net loss to $1.6 million from $7.7 million in the prior year, with Adjusted EBITDA increasing to $4.0 million.
-
Raised Full-Year Product Revenue Guidance
Increased full-year 2026 product revenue guidance to a range of $227 million to $231 million, up from the previous range of $224 million to $228 million, reflecting 10% to 12% year-over-year growth.
-
New Strategic Supply Agreement
Secured a new four-year supply agreement with Établissement Français du Sang (EFS) for its INTERCEPT Blood System for platelets, plasma, and the INT200 device.
-
Planned CEO Succession
Announced that COO Vivek Jayaraman will become President and CEO effective July 1, 2026, with current CEO William Greenman transitioning to Executive Chairman of the Board.
Analysis · CERS · Industrial Applications And Services
Cerus Corporation delivered a strong first quarter, significantly improving its financial performance with substantial revenue growth and a reduced net loss. The decision to raise full-year product revenue guidance signals management's confidence in continued momentum. Additionally, the new four-year supply agreement with EFS provides long-term revenue visibility. The planned CEO transition appears to be a smooth succession, with the current COO stepping into the top role and the existing CEO becoming Executive Chairman, which can be viewed positively as it ensures continuity and leverages experienced leadership.
At the time of this filing, CERS was trading at $2.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $406.7M. The 52-week trading range was $1.15 to $2.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.